What is HC Wainwright’s Forecast for RNAZ Q1 Earnings?

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for TransCode Therapeutics in a report issued on Wednesday, December 18th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings per share of ($1.48) for the quarter. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($60.73) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q2 2025 earnings at ($1.64) EPS, Q3 2025 earnings at ($1.02) EPS and Q4 2025 earnings at ($0.78) EPS.

TransCode Therapeutics Trading Down 2.3 %

Shares of RNAZ stock opened at $3.76 on Friday. TransCode Therapeutics has a 12 month low of $3.21 and a 12 month high of $264.00. The stock has a 50 day moving average of $380.38 and a two-hundred day moving average of $553.50.

Institutional Inflows and Outflows

An institutional investor recently raised its position in TransCode Therapeutics stock. Sheets Smith Wealth Management grew its holdings in TransCode Therapeutics, Inc. (NASDAQ:RNAZ) by 149.0% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 50,138 shares of the company’s stock after buying an additional 30,000 shares during the quarter. Sheets Smith Wealth Management owned 0.29% of TransCode Therapeutics worth $29,000 as of its most recent filing with the SEC.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.